logo

TCRX

TScan TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

TCRX Profile

Tscan Therapeutics, Inc.

A preclinical-stage biopharmaceutical company that developing T cell receptor engineered T cell therapies for the treatment of cancer

Pharmaceutical
04/17/2018
07/16/2021
NASDAQ Stock Exchange
194
12-31
Common stock
830 Winter Street, Waltham, Massachusetts 02451
--
TScan Therapeutics, Inc., was incorporated in Delaware on April 17, 2018. The company is a preclinical stage biopharmaceutical company focused on developing powerful T cell receptor engineered T cells or TCR-T therapies for the treatment of cancer patients.